Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

Launched by BEIJING FRIENDSHIP HOSPITAL · Apr 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain substances in the blood, known as metabolites, can help diagnose multiple types of cancer early on. Researchers are collecting plasma samples from patients who have been diagnosed with various cancers, such as lung, breast, and colorectal cancers, to build a database of these metabolites. The goal is to find reliable markers that could lead to safer and easier screening methods for people at high risk of developing multiple cancers.

To participate in this trial, you need to be at least 45 years old and can either be someone already diagnosed with cancer (who has not yet received treatment) or a healthy individual with normal physical exam results. Participants will provide blood samples and share their medical history. It’s important to know that certain health conditions, like severe infections or autoimmune diseases, may exclude someone from joining the study. Overall, this trial aims to improve early cancer detection, which could potentially save lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Multi-Cancer Group:
• • Patients with a confirmed diagnosis based on the clinical "gold standard".
• • Collection of plasma samples prior to treatment.
• • Availability of complete clinical data.
• * Control Group:
• • Individuals with no abnormalities in routine physical examinations and relevant clinical tests.
• • Age ≥ 45 years.
• • Availability of complete clinical data.
• Exclusion Criteria:
• • Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.
• • Coexistence of other systemic tumors.
• • Absence of plasma sample collection before treatment.
• • Pregnancy status.
• • No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion).
• • Patients with severe acute infections.
• • Patients with severe anemia.
• • Patients with severe liver or kidney dysfunction.
• • Patients with autoimmune deficiency diseases.
• • Patients with Hyperlipidemia.
• • Patients received contrast agent injection before blood draw.
• • Patients with psychiatric disorders.